Olema Pharmaceuticals (OLMA) Reports KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity Oct 12, 2023 07:02AM
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity Oct 12, 2023 07:01AM
Olema Pharmaceuticals (OLMA) Announces Expansion of Collaboration Agreement with Novartis Oct 10, 2023 07:02AM
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis Oct 10, 2023 07:00AM
Olema Pharmaceuticals (OLMA) Announces New Preclinical KAT6 Inhibitor Data Sep 20, 2023 07:29AM


Sep 20, 2023 07:29AM Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 6, 2023 04:30PM Olema Oncology to Participate in Upcoming Investor Conferences
Sep 5, 2023 07:31AM Olema Pharmaceuticals (OLMA) Announces $180M in New Financing
Sep 5, 2023 07:30AM Olema Oncology Announces Combined Financing for Up to $180 Million
Aug 8, 2023 04:03PM Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update